Why did Japanese guidance favour early H. pylori treatment for stomach cancer prevention?

Japan's 2024 guideline says all Helicobacter pylori infections should be treated, and it strongly recommends treating at an early age for stomach-cancer prevention. The core message is about timing and expectations, not a guarantee: the protection is expected to be greatest before the stomach lining has developed serious changes, but treatment does not remove all future risk. People who are successfully treated can still develop stomach cancer, which is why the same guidance separately recommends long-term follow-up after treatment.

Why earlier treatment is expected to help more

Helicobacter pylori is a stomach bacterium that can be picked up in childhood and can keep the stomach lining inflamed for years. If the infection persists, the inflammation can progress: the lining can become thinner, a change called atrophic gastritis, and some areas may begin to resemble intestinal lining, a change called intestinal metaplasia. The guidelines explain that clearing the infection before these more advanced changes appear is expected to give the greatest cancer protection. Follow-up studies point the same direction. In a large Korean study, people treated before age 45 had roughly two-thirds lower stomach-cancer risk during follow-up than people treated at 75 or older, and the advantage was smaller in each older treatment-age group. A separate Taiwanese analysis estimated that each year earlier a person was treated was linked to about 3% lower risk.

These age comparisons come from observational follow-up, not from a randomized experiment that assigned some people to early treatment and others to delayed treatment. The guideline itself states that randomized trials comparing early versus delayed eradication are lacking. This matters because people treated at different ages may differ in other ways, so the observed pattern supports earlier treatment but cannot by itself prove that timing alone caused the reduction. The panel's strong recommendation is therefore a judgment based on the overall pattern and the biology of the infection, not a measured guarantee from a head-to-head trial.

What treatment did and did not do in a large treated group

A public-hospital database study in Hong Kong followed 73,237 people who were treated for H. pylori infection. Over a median follow-up of 7.6 years, 200 of them, or 0.27%, still developed stomach cancer. That is the key limit: treatment greatly reduced but did not eliminate the risk. Compared with an age- and sex-matched general population, people aged 60 or older who were treated had an 18% lower stomach-cancer rate overall. The benefit became clearer with time; ten or more years after treatment, the treated group's rate was only about one-third to two-fifths of the rate expected in the general population, depending on age group. Even then, some cancers still occurred.

Why long-term follow-up and testing cautions matter

Because no test can promise that all risk is gone, the guidelines recommend long-term surveillance for everyone after successful treatment. They also say it is currently impossible to identify a group of patients for whom surveillance is unnecessary; follow-up should be planned individually according to factors such as severe thinning of the stomach lining, intestinal metaplasia, or a history of stomach cancer. The guidance is also clear that testing alone is not prevention. A blood test for antibodies against H. pylori or a marker called pepsinogen has insufficient evidence to support stomach-cancer prevention unless a positive result leads to proper follow-up, including treatment and endoscopic monitoring; annual repeat blood testing is not recommended. Cancer screening with x-ray or endoscopy can identify people with H. pylori-related gastritis and refer them for eradication, which the guidelines describe as its primary preventive role. Endoscopic images can also help classify whether an infection is currently present, but confirming infection may require other diagnostic tests, and imaging alone does not prove that screening prevents stomach cancer.